MARKET

SCTL

SCTL

SOCIETAL CDMO INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9240
-0.0759
-7.59%
Closed 16:00 05/13 EDT
OPEN
0.9661
PREV CLOSE
0.9999
HIGH
1.030
LOW
0.9103
VOLUME
114.81K
TURNOVER
69.59K
52 WEEK HIGH
2.670
52 WEEK LOW
0.8835
MARKET CAP
52.33M
P/E (TTM)
-2.9427
1D
5D
1M
3M
1Y
5Y
Recap: Societal CDMO Q1 Earnings
Societal CDMO (NASDAQ:SCTL) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Societal CDMO beat estimated earnings by 11.11%, reporting an EPS of $-0.08 versus an e...
Benzinga · 4d ago
Societal CDMO GAAP EPS of -$0.08 beats by $0.01, revenue of $21.2M beats by $1.78M
Societal CDMO press release (NASDAQ:SCTL): Q1 GAAP EPS of -$0.08 beats by $0.01. Revenue of $21.2M (+26.2% Y/Y) beats by $1.78M.
Seekingalpha · 4d ago
-- Earnings Flash (SCTL) SOCIETAL CDMO Reports Q1 Revenue $21.2M, vs. Street Est of $19.4M
MT Newswires · 4d ago
Q1 2022 Earnings Preview
Societal CDMO (NASDAQ:SCTL) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $19.42M
Seekingalpha · 5d ago
Earnings Outlook For Societal CDMO
Societal CDMO (NASDAQ:SCTL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Societal CDMO will report an earnings per share (EPS) of $-0.09.
Benzinga · 5d ago
BRIEF-Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With Infectopharm For Ritalin La® In Europe
reuters.com · 05/05 11:28
Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe
Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023SAN DIEGO, and GAINESVILLE, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organizat...
GlobeNewswire · 05/05 11:00
Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022
Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., May 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturin...
GlobeNewswire · 05/04 20:05
More
No Data
Learn about the latest financial forecast of SCTL. Analyze the recent business situations of SOCIETAL CDMO INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SCTL stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.
High6.00
Average4.500
Low3.000
Current 0.9240
EPS
Actual
Estimate
-0.08-0.05-0.020.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 126
Institutional Holdings: 35.63M
% Owned: 63.09%
Shares Outstanding: 56.63M
TypeInstitutionsShares
Increased
20
3.19M
New
6
277.07K
Decreased
18
1.52M
Sold Out
10
1.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.62%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Non-Executive Chairman/Independent Director
Wayne Weisman
President/Chief Executive Officer/Director
J. David Enloe
Chief Financial Officer
Ryan Lake
Independent Director
William Ashton
Independent Director
Michael Berelowitz
Independent Director
Winston Churchill
Independent Director
James Miller
Independent Director
Laura Parks
Independent Director
Bryan Reasons
No Data
No Data
About SCTL
Recro Pharma, Inc. is a contract development and manufacturing organization (CDMO). The Company is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. It also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. It operates in one segment. It provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The Company develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:SCTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCTL stock methods without spending real money on the virtual paper trading platform.